<DOC>
<DOCNO>EP-0626171</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Oxytetracycline or doxycycline injectable solution containing PVP and N-methylpyrrolidone and/or 2-pyrrolidone.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K900	A61K900	A61K3165	A61K3165	A61K4700	A61K4700	A61K4702	A61K4702	A61K4716	A61K4718	A61K4722	A61K4722	A61K4732	A61K4732	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K9	A61K9	A61K31	A61K31	A61K47	A61K47	A61K47	A61K47	A61K47	A61K47	A61K47	A61K47	A61K47	A61K47	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to an injectable solution for intravenous or intramuscular administration to animals with a content, based on 100 ml of solution, of 5 to 25 g of oxytetracycline or doxycycline, each as magnesium complex, 5 to 25 g of polyvinylpyrrolidone, the required amount of an inorganic or organic base to adjust the pH of 5.0 to 9.5, and conventional additives in an aqueous/organic solvent phase, in which the solvent phase consists of 8 to 66 g of N-methylpyrrolidone and/or 2-pyrrolidone, preferably in a mixing ratio of 92:8 to 70:30 by weight, and water, based on 100 ml of solution, and to a process for the production thereof.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
DOERNHOEFER WINFRIED
</APPLICANT-NAME>
<APPLICANT-NAME>
EMBRECHTS ERWIN
</APPLICANT-NAME>
<APPLICANT-NAME>
DOERNHOEFER, WINFRIED
</APPLICANT-NAME>
<APPLICANT-NAME>
EMBRECHTS, ERWIN
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DOERNHOEFER WINFRIED
</INVENTOR-NAME>
<INVENTOR-NAME>
EMBRECHTS ERWIN
</INVENTOR-NAME>
<INVENTOR-NAME>
DOERNHOEFER, WINFRIED
</INVENTOR-NAME>
<INVENTOR-NAME>
EMBRECHTS, ERWIN
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
